Murtaza Salem1, Mohammed Sayed Hosny2, Federica Francia2, Morad Sallam2, Athanasios Saratzis3, Prakash Saha2, Sanjay Patel2, Said Abisi2, Hany Zayed2. 1. Department of Vascular Surgery, Queens Medical Centre, Nottingham University Hospitals NHS Foundation Trust, Nottingham, NG7 2UH, UK. m.salem@doctors.org.uk. 2. Department of Vascular Surgery, Level 1 North Wing, Guys & St Thomas' NHS Foundation Trust, St Thomas' Hospital, Westminster Bridge Rd, London, SE1 7EH, UK. 3. Leicester Biomedical Research Centre (BRC), Leicester Vascular Institute and National Institute for Health Research (NIHR), Leicester, UK.
Abstract
PURPOSE: Despite advances in endovascular management of aorto-iliac occlusive disease (AIOD) including covered endovascular reconstruction of aortic bifurcation (CERAB) techniques, guidelines for management of symptomatic Trans-Atlantic Inter-Society Consensus (TASC II) type C/D lesions favour open surgical revascularisation. This meta-analysis investigates outcomes in patients with TASC II C/D lesions treated with open bypass procedures (OS), standard endovascular treatments (SEV) or CERAB. METHODS: Multiple databases (MEDLINE, EMBASE and the Cochrane database) were searched to identify studies reporting endovascular and open treatment of extensive AIOD. Studies were independently assessed. Outcomes reported included 30-day morbidity/mortality and patency rates. RESULTS: A total of 9319 patients undergoing intervention for extensive AIOD were identified from 66 studies. Median patient age was 64 years (n = 3204) for SEV, 58 years (n = 240) for CERAB and 59 years for OS (n = 5875). Pooled meta-analysis for 30-day morbidity in patients undergoing SEV, CERAB and OS was 9, 10 and 15%, respectively. Thirty-day mortality rate was 0.79, 0 and 3% in the SEV, CERAB and OS groups, respectively. In these groups, one-year primary and secondary patency was 90, 88, 96 and 96, 97, and 97% whilst three-year primary and secondary patency was 78, 82, 93 and 93, 97, 97% respectively. Five-year primary and secondary patency was 71 and 89% for SEV and 88 and 95% for OS, respectively. CERAB data were only available to 3 years. CONCLUSIONS: This meta-analysis shows that thirty-day morbidity and mortality favours endovascular techniques. Primary patency remains better with OS in both early and midterms;; however, secondary patency is comparable in all groups. These findings suggest that SEV/CERAB may be considered as an alternative to OS in higher-risk patients.
PURPOSE: Despite advances in endovascular management of aorto-iliac occlusive disease (AIOD) including covered endovascular reconstruction of aortic bifurcation (CERAB) techniques, guidelines for management of symptomatic Trans-Atlantic Inter-Society Consensus (TASC II) type C/D lesions favour open surgical revascularisation. This meta-analysis investigates outcomes in patients with TASC II C/D lesions treated with open bypass procedures (OS), standard endovascular treatments (SEV) or CERAB. METHODS: Multiple databases (MEDLINE, EMBASE and the Cochrane database) were searched to identify studies reporting endovascular and open treatment of extensive AIOD. Studies were independently assessed. Outcomes reported included 30-day morbidity/mortality and patency rates. RESULTS: A total of 9319 patients undergoing intervention for extensive AIOD were identified from 66 studies. Median patient age was 64 years (n = 3204) for SEV, 58 years (n = 240) for CERAB and 59 years for OS (n = 5875). Pooled meta-analysis for 30-day morbidity in patients undergoing SEV, CERAB and OS was 9, 10 and 15%, respectively. Thirty-day mortality rate was 0.79, 0 and 3% in the SEV, CERAB and OS groups, respectively. In these groups, one-year primary and secondary patency was 90, 88, 96 and 96, 97, and 97% whilst three-year primary and secondary patency was 78, 82, 93 and 93, 97, 97% respectively. Five-year primary and secondary patency was 71 and 89% for SEV and 88 and 95% for OS, respectively. CERAB data were only available to 3 years. CONCLUSIONS: This meta-analysis shows that thirty-day morbidity and mortality favours endovascular techniques. Primary patency remains better with OS in both early and midterms;; however, secondary patency is comparable in all groups. These findings suggest that SEV/CERAB may be considered as an alternative to OS in higher-risk patients.
Authors: L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes; Kevin Bell; Joseph Caporusso; Isabelle Durand-Zaleski; Kimihiro Komori; Johannes Lammer; Christos Liapis; Salvatore Novo; Mahmood Razavi; Johns Robbs; Nicholaas Schaper; Hiroshi Shigematsu; Marc Sapoval; Christopher White; John White; Denis Clement; Mark Creager; Michael Jaff; Emile Mohler; Robert B Rutherford; Peter Sheehan; Henrik Sillesen; Kenneth Rosenfield Journal: Eur J Vasc Endovasc Surg Date: 2006-11-29 Impact factor: 7.069
Authors: Michael S Conte; Andrew W Bradbury; Philippe Kolh; John V White; Florian Dick; Robert Fitridge; Joseph L Mills; Jean-Baptiste Ricco; Kalkunte R Suresh; M Hassan Murad; Victor Aboyans; Murat Aksoy; Vlad-Adrian Alexandrescu; David Armstrong; Nobuyoshi Azuma; Jill Belch; Michel Bergoeing; Martin Bjorck; Nabil Chakfé; Stephen Cheng; Joseph Dawson; Eike S Debus; Andrew Dueck; Susan Duval; Hans H Eckstein; Roberto Ferraresi; Raghvinder Gambhir; Mauro Gargiulo; Patrick Geraghty; Steve Goode; Bruce Gray; Wei Guo; Prem C Gupta; Robert Hinchliffe; Prasad Jetty; Kimihiro Komori; Lawrence Lavery; Wei Liang; Robert Lookstein; Matthew Menard; Sanjay Misra; Tetsuro Miyata; Greg Moneta; Jose A Munoa Prado; Alberto Munoz; Juan E Paolini; Manesh Patel; Frank Pomposelli; Richard Powell; Peter Robless; Lee Rogers; Andres Schanzer; Peter Schneider; Spence Taylor; Melina V De Ceniga; Martin Veller; Frank Vermassen; Jinsong Wang; Shenming Wang Journal: Eur J Vasc Endovasc Surg Date: 2019-06-08 Impact factor: 7.069
Authors: Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais Journal: Eur Heart J Date: 2018-03-01 Impact factor: 29.983
Authors: Jörn O Balzer; Verena Gastinger; Ralf Ritter; Christopher Herzog; Martin G Mack; Thomas Schmitz-Rixen; Thomas J Vogl Journal: Eur Radiol Date: 2005-04-05 Impact factor: 5.315
Authors: Robert W Chang; Philip P Goodney; Jennie H Baek; Brian W Nolan; Eva M Rzucidlo; Richard J Powell Journal: J Vasc Surg Date: 2008-06-24 Impact factor: 4.268
Authors: Ahsan T Ali; J Gregory Modrall; Jorge Lopez; John G Brawley; M Burress Welborn; G Patrick Clagett; R James Valentine; Mark R Jackson Journal: J Vasc Surg Date: 2003-09 Impact factor: 4.268